Edition:
India

Rigel Pharmaceuticals Inc (RIGL.OQ)

RIGL.OQ on NASDAQ Stock Exchange Global Select Market

4.06USD
19 Apr 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$4.06
Open
--
Day's High
--
Day's Low
--
Volume
244,137
Avg. Vol
587,474
52-wk High
$4.71
52-wk Low
$2.15

Latest Key Developments (Source: Significant Developments)

Rigel Announces Pricing Of Public Offering Of Common Stock
Friday, 20 Apr 2018 

April 19 (Reuters) - Rigel Pharmaceuticals Inc ::RIGEL ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.PUBLIC OFFERING OF 16,000,000 SHARES OF ITS COMMON STOCK, OFFERED AT A PRICE OF $3.90 PER SHARE TO PUBLIC.  Full Article

Rigel Intends To Offer & Sell Up To 15 Mln Shares Of Its Stock In Underwritten Public Offering
Thursday, 19 Apr 2018 

April 18 (Reuters) - Rigel Pharmaceuticals Inc ::RIGEL ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.RIGEL PHARMACEUTICALS INC - INTENDS TO OFFER & SELL UP TO 15 MILLION SHARES OF ITS STOCK IN AN UNDERWRITTEN PUBLIC OFFERING.RIGEL PHARMACEUTICALS INC - PROCEEDS FROM OFFERING TO BE USED FOR ACTIVITIES IN CONNECTION WITH COMMERCIAL LAUNCH OF TAVALISSE IN UNITED STATES.  Full Article

Rigel Pharmaceuticals NDA For Tavalisse Approved By FDA
Tuesday, 17 Apr 2018 

April 17 (Reuters) - U.S. Food And Drug Administration::RIGEL PHARMACEUTICALS NDA FOR TAVALISSE APPROVED BY FDA.  Full Article

Rigel Makes Statement Regarding Website Error
Friday, 13 Apr 2018 

April 12 (Reuters) - Rigel Pharmaceuticals Inc ::RIGEL MAKES STATEMENT REGARDING WEBSITE ERROR.FDA IS CONTINUING ITS REVIEW OF NDA AND PDUFA ACTION DATE FOR FOSTAMATINIB NDA IS APRIL 17.DUE TO AN ERROR, INACCURATE INFORMATION WAS DISPLAYED REGARDING U.S. FDA'S REVIEW OF NDA FOR FOSTAMATINIB.CO'S WEBSITE HAS BEEN CORRECTED.  Full Article

Rigel Pharma Q4 Loss Per Share $0.18
Wednesday, 7 Mar 2018 

March 6 (Reuters) - Rigel Pharmaceuticals Inc ::RIGEL ANNOUNCES FOURTH QUARTER AND YEAR END 2017 FINANCIAL RESULTS AND PROVIDES COMPANY UPDATE.Q4 LOSS PER SHARE $0.18.‍THERE WERE NO CONTRACT REVENUES FROM COLLABORATIONS IN Q4 OF 2017​.  Full Article

Rigel to Provide Business Review and Updated Phase 2 Results for Fostamatinib
Thursday, 4 Jan 2018 

Jan 4 (Reuters) - Rigel Pharmaceuticals Inc ::RIGEL PHARMACEUTICALS - ‍FDA HAS CONFIRMED IT DOES NOT PLAN TO CONVENE ONCOLOGY DRUGS ADVISORY COMMITTEE MEETING TO DISCUSS NDA FOR FOSTAMATINIB​.RIGEL PHARMACEUTICALS INC - ACTION DATE FOR FDA TO COMPLETE ITS REVIEW FOR FOSTAMATINIB IS APRIL 17, 2018 UNDER PDUFA.  Full Article

Rigel Announces Resignation Of Ryan Maynard, Executive Vice President And CFO Effective December 31, 2017
Friday, 15 Dec 2017 

Dec 15 (Reuters) - Rigel Pharmaceuticals Inc ::RIGEL ANNOUNCES DEPARTURE OF CHIEF FINANCIAL OFFICER.RESIGNATION OF RYAN MAYNARD, EXECUTIVE VICE PRESIDENT AND CHIEF FINANCIAL OFFICER, EFFECTIVE DECEMBER 31, 2017.COMPANY HAS INITIATED AN EXTERNAL SEARCH FOR ITS NEXT CHIEF FINANCIAL OFFICER.NELSON CABATUAN, RIGEL'S VICE PRESIDENT, FINANCE WILL SERVE AS COMPANY'S INTERIM PRINCIPAL ACCOUNTING OFFICER.  Full Article

Rigel announces Q3 loss of $0.14 per share
Wednesday, 8 Nov 2017 

Nov 7 (Reuters) - Rigel Pharmaceuticals Inc :Rigel announces third quarter 2017 financial results and provides company update.Q3 loss per share $0.14.  Full Article

Rigel announces pricing of public offering of common stock
Thursday, 5 Oct 2017 

Oct 4 (Reuters) - Rigel Pharmaceuticals Inc :Rigel announces pricing of public offering of common stock.Says public offering of 18.1 million common shares priced at $3.35 per share.  Full Article

Rigel Pharmaceuticals q2 loss per share $0.15
Wednesday, 3 Aug 2016 

Rigel Pharmaceuticals Inc : Q2 loss per share $0.15 . Expects cash, cash equivalents and short-term investments as Of June 30 to be sufficient to fund operations into q3 of 2017 . Rigel pharmaceuticals inc qtrly revenues $13.6 million versus $7.4 million .Q2 earnings per share view $-0.20 -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Rigel Announces Pricing Of Public Offering Of Common Stock

* PUBLIC OFFERING OF 16,000,000 SHARES OF ITS COMMON STOCK, OFFERED AT A PRICE OF $3.90 PER SHARE TO PUBLIC Source text for Eikon: Further company coverage: